Biomarkers and Clinical Research

Epigenetic Biomarkers

Epigenetic biomarkers are pivotal in understanding how environmental factors and lifestyle choices influence gene expression without altering DNA sequences. These biomarkers, including DNA methylation, histone modifications, and non-coding RNAs, provide insights into disease susceptibility, progression, and response to therapies. In cancer research, epigenetic biomarkers like hypermethylation of tumor suppressor genes or dysregulated microRNAs are associated with tumor initiation and progression. They offer potential targets for novel therapeutic interventions and prognostic indicators for patient outcomes. Beyond oncology, epigenetic biomarkers are studied in various diseases, including cardiovascular disorders, neurodegenerative diseases, and autoimmune conditions. They contribute to personalized medicine by predicting individual responses to treatments and guiding therapeutic strategies tailored to patient-specific epigenetic profiles. The discovery and validation of epigenetic biomarkers hold promise for advancing precision medicine, facilitating early disease detection, and improving patient care through targeted interventions that address underlying molecular mechanisms.